# Mitch Dowsett

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mitch-dowsett/

## Facts

| Field | Value |
| --- | --- |
| Citations | 112,249 |
| Field | Estrogen and related hormone effects |
| h-index | 147 |
| i10-index | 621 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5057689412 |
| ORCID iD | https://orcid.org/0000-0003-4122-744X |
| Works | 1,593 |

## Researcher papers

Showing 12 of 14.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer](https://scholariq.org/papers/mutation-tracking-in-circulating-tumor-dna-predicts-relapse-in-early-breast/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Aromatase Inhibitors in Breast Cancer](https://scholariq.org/papers/aromatase-inhibitors-in-breast-cancer/)
- [Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven](https://scholariq.org/papers/phase-i-clinical-trial-of-a-selective-inhibitor-of-cyp17-abiraterone-acetate/)
- [Proliferation Marker Ki-67 in Early Breast Cancer](https://scholariq.org/papers/proliferation-marker-ki-67-in-early-breast-cancer/)
- [Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial](https://scholariq.org/papers/neoadjuvant-treatment-of-postmenopausal-breast-cancer-with-anastrozole-tamoxifen/)
- [Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group](https://scholariq.org/papers/assessment-of-ki67-in-breast-cancer-updated-recommendations-from-the/)
- [Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer](https://scholariq.org/papers/prognostic-value-of-ki67-expression-after-short-term-presurgical-endocrine/)

## Researcher topics

- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Risks and Factors](https://scholariq.org/topics/cancer-risks-and-factors/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.